Search
Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10782ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10792ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Bolivia/559/2013 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB11034ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Switzerland/9715293/2013 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB11035ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen
go.drugbank.com/drugs/DB11037ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11040ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11042ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB11046ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Maduramicin
go.drugbank.com/drugs/DB11525ExperimentalVet approvedMaduramicin is an antiprotozoal agent used in veterinary medicine as prophylaxis against coccidiosis. … It is a naturally occurring compound which was first isolated from the actinomycete, Actinomadura rubra.
Utidelone
go.drugbank.com/drugs/DB17575InvestigationalUtidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering.[A257544,A257549] It is under investigation in clinical trials for various cancers.